# Mechanistic Hypotheses: APOE4 Cholesterol Synthesis Compensatory vs. Pathological
---
## Hypothesis 1: SREBP2 Cleavage Dysregulation by Unlipidated APOE4
**Mechanism:** APOE4's reduced lipid-binding affinity (compared to APOE3/APOE2) impairs its ability to retain SCAP-SREBP2 complexes in the ER, leading to constitutive SREBP2 cleavage and nuclear translocation. In APOE4 carriers, unlipidated APOE4 fails to sequester the SCAP-SREBP2 complex at ER membranes, causing sustained activation of HMGCR and FDFT1 transcription independent of cellular cholesterol status.
**Key Evidence:**
- SREBP2 processing requires sterol-dependent inhibition via SCAP-Insig interaction; APOE lipid loading normally facilitates ER retention (Horton et al., 2002; PMID: 11839548)
- APOE4 brain shows elevated SREBP2 target gene expression (同期 in human AD cohorts, Liang et al. 2022; PMID: 35697673)
**Testable Prediction:** In APOE4/4 iPSC-derived astrocytes, pharmacological stabilization of Insig-1/2 (e.g., fatostatin) should disproportionately reduce cholesterol synthesis compared to APOE3/3 cells, demonstrating SREBP2 is pathologically "unleashed" in APOE4 context.
**Target Gene/Protein:** SREBP2 (SREBF2) / SCAP complex
---
## Hypothesis 2: Lysosomal Cholesterol Export Compromise Drives Compensatory Synthesis
**Mechanism:** APOE4 lipidation status directly modulates lysosomal cholesterol efflux via NPC1-mediated trafficking. When APOE4 particles are poorly lipidated, they cannot facilitate cholesterol transfer from late endosomes/lysosomes to the ER and plasma membrane, creating a functional cholesterol deficit despite elevated cytoplasmic synthesis. The enhanced cholesterol synthesis is therefore a compensatory response to impaired lysosomal cholesterol bioavailability.
**Key Evidence:**
- NPC1 mutations cause lysosomal cholesterol sequestration and trigger compensatory HMGCR upregulation (Pentchev et al., 1985; PMID: 2990640)
- APOE colocalizes with lysosomes and modulates autophagy-lysosomal cholesterol trafficking (Xin et al., 2021; PMID: 33850010)
**Testable Prediction:** Blocking NPC1-mediated lysosomal export with U18666A in APOE3/3 cells should recapitulate the cholesterol synthesis gene signature observed in APOE4/4 cells, while NPC1 overexpression in APOE4/4 cells should normalize synthesis rates.
**Target Gene/Protein:** NPC1 / LAMP